Multiple Myeloma

Relapsed

HEMMYL0038
Phase II
Magrolimab
Combinations in Relapsed/Refractory Multiple Myeloma
PI: Liedtke
Sponsor: Pending

CCT5046
Phase I CC-98633
BCMA Targeted
NEX-T CAR T
Cells, in Relapsed
and/or Refractory
Multiple Myeloma
PI: Liedtke
Sponsor: Juno
Therapeutics, Inc.

CCT5030
Phase I
ALLO-715 Eval
Anti-BCMA
Allogeneic CAR
T Cell Tx in
Relapsed/
Refractory
Multiple
Myeloma
PI: Liedtke
Sponsor: Allogene

CCT5025
Phase III bb2121
vs SoC Triplet
Regimens in
Relapsed &
Refractory
Multiple Myeloma
(RRMM)
(KarMMa-3)
PI: Liedtke
Sponsor: Celgene
Corporation

HEMMYL0032
Phase I
SEA-BCMA in
Relapsed or
Refractory
Multiple
Myeloma
PI: Liedtke
Sponsor: Seattle
Genetics

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold